A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Active, not recruiting · Phase 2 · NCT06672978
Conditions: Acute Pyelonephritis, Complicated Urinary Tract Infection
At a glance
- Research payments reported, 2025
- $40,201
- U.S. investigators named
- 5
- Sites paid
- 1
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (with Biomedical Advanced Research and Development Authority)
- Tested
- Meropenem-Vaborbactam (drug), Antibiotics (drug)
- Dates
- Started 2025-06-03; completion 2027-07
- Results posted
- Not yet
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).
From ClinicalTrials.gov, last updated 2026-09-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Melinta Therapeutics, LLC reported $40,201 in research payments for this study in 2025 (62 payments).
Products named: Vabomere
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Antonio C. Arrieta, M.D. Pediatric Infectious Disease · Orange, CA
- Jaime G. Deville, M.D. Pediatric Infectious Disease · Los Angeles, CA
- John H. Makari, MD Urology · Omaha, NE
- Ankita P. Desai, MD Pediatric Infectious Disease · Cleveland, OH
- David M. Spiro, MD Pediatric Emergency Medicine · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.